Minami T, Tohno Y, Tohno S, Utsumi M, Yamada M, Hashii K, Tateyama I, Kadota E, Okazaki Y
Department of Clinical Chemistry, Faculty of Pharmaceutical Sciences, Kinki University, Osaka, Japan.
Biol Trace Elem Res. 1997 Jul-Aug;58(1-2):77-83. doi: 10.1007/BF02910668.
Tissue platinum (Pt) levels were measured in tumor-bearing patients treated with either cisplatin or carboplatin. Cisplatin was given by intra-arterial, intraperitoneal, and intravenous (iv) administrations. After death, vertebrae and intervertebral disks were removed from eight human subjects, and livers and kidneys were removed from the half of them. When cisplatin was administered intraperitoneally, Pt of the liver was higher than that of the kidney, and a high content of Pt was detected in the vertebra by comparing with the other administration methods. At the intra-arterial administration of cisplatin, Pt was mainly accumulated in the kidney. At the iv administration of cisplatin, a high level of Pt was found in the vertebra and intervertebral disk, especially at the highest value at 10.31 micrograms/g in the intervertebral disk of one case, whereas a low level of Pt was detected in the liver. On the contrary, it was found that the iv administration of carboplatin did not result in high accumulations of Pt in the liver, kidney, intervertebral disk, and vertebra. Therefore, Pt is accumulated in different organs, depending on the way cisplatin is administered, but Pt is accumulated least in them by the administration of carboplatin.
对接受顺铂或卡铂治疗的荷瘤患者的组织铂（Pt）水平进行了测量。顺铂通过动脉内、腹腔内和静脉内（iv）给药。死亡后，从8名人类受试者身上取出椎骨和椎间盘，其中一半受试者还取出了肝脏和肾脏。当顺铂腹腔内给药时，肝脏中的Pt高于肾脏，与其他给药方法相比，在椎骨中检测到高含量的Pt。顺铂动脉内给药时，Pt主要积聚在肾脏。顺铂静脉内给药时，在椎骨和椎间盘中发现高水平的Pt，尤其是1例患者的椎间盘中最高值达到10.31微克/克，而肝脏中检测到的Pt水平较低。相反，发现卡铂静脉内给药不会导致Pt在肝脏、肾脏、椎间盘和椎骨中高度积聚。因此，根据顺铂的给药方式，Pt在不同器官中积聚，但通过卡铂给药，Pt在这些器官中的积聚最少。
